Simon Cervenka
Professor at Institutionen för medicinska vetenskaper; Psykiatri
- E-mail:
- simon.cervenka@neuro.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 10
- Postal address:
- Akademiska sjukhuset, ingång 10, plan
751 85 UPPSALA
More information is available to staff who log in.
Short presentation
I am professor of Psychiatry at Uppsala University, and senior consultant at the psychiatry clinic, Uppsala Akademiska Hospital. I combine research, teaching and clinical work.
Keywords
- clinical research
- molecular imaging
- psychiatry
- psychosis
- schizophrenia
Biography
MD, Uppsala University 1999
Licence to Practice Medicine 2002
PhD, Karolinska Institutet 2008
Specialist in Psychiatry 2009
Associate Professor of Psychiatry, Karolinska Institutet 2016
Research
My research focuses on the biological processes behind the symptoms of psychiatric disorders, with particular focus on psychosis and schizophrenia. The long-term goal of my work is to develop new diagnostic tools and treatment approaches.
Psychotic disorders affect individuals at a young age, causing great suffering and often severe loss of function. With current treatment, only a minority of patients recover. There is an urgent need for new treatment approaches that not only dampen symptoms, but can change the disease course. Moreover, given the heterogenous nature of psychiatric conditions we need tools for treatment stratification, i.e. finding the right treatment for the right patient, at the right time. Addressing these unmet medical needs requires an improved understanding of the underlying disease mechanisms.
A key methodological platform in my research is positron emission tomography (PET), which enables quantification of biochemical markers in brain in vivo. I am also part of collaborative projects using structural and functional magnetic resonance imaging (MRI) and biomarkers in blood and cerebrospinal fluid (CSF). The biological measures are correlated with detailed clinical phenotyping, including assessment of different aspects of cognitive function. Clinical studies are performed in close collaboration with health care partners.
Certain research questions require large samples to allow for robust inferences. I am actively engaged in projects pooling PET data across research centers, and have contributed to large-scale collaborations on different MR imaging modalities. An important aim going forward is to transition from analyses based on diagnostic status to identify mechanistically informative markers for clinical use.
Don’t hesitate to contact me if you are interested in joining this work!
Publications
Recent publications
- Cerebrospinal fluid proteomic signatures are associated with symptom severity of first-episode psychosis (2024)
- Lower complement C1q levels in first-episode psychosis and in schizophrenia (2024)
- Cognitive Function and Variability in Antipsychotic Drug-Naive Patients With First-Episode Psychosis (2024)
- Cartesiansk dualism i ohälsans otjänst – nytt steg efterlyses (2024)
- Immunological protein profiling of first-episode psychosis patients identifies CSF and blood biomarkers correlating with disease severity (2023)
All publications
Articles
- Cerebrospinal fluid proteomic signatures are associated with symptom severity of first-episode psychosis (2024)
- Lower complement C1q levels in first-episode psychosis and in schizophrenia (2024)
- Cognitive Function and Variability in Antipsychotic Drug-Naive Patients With First-Episode Psychosis (2024)
- Cartesiansk dualism i ohälsans otjänst – nytt steg efterlyses (2024)
- Immunological protein profiling of first-episode psychosis patients identifies CSF and blood biomarkers correlating with disease severity (2023)
- Preanalytic handling of clinical blood samples in assessing immunological proteins - Role of storage duration (2023)
- Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers. (2023)
- CSF dopamine is elevated in first-episode psychosis and associates to symptom severity and cognitive performance. (2023)
- Disrupted-in-schizophrenia 1 (DISC1) protein aggregates in cerebrospinal fluid are elevated in first-episode psychosis patients. (2023)
- Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium (2023)
- Metacognitive training for negative symptoms (2023)
- Olfactory Cues of Naturally Occurring Systemic Inflammation (2023)
- Cytomegalovirus infection associated with lower IQ in adolescent patients with schizophrenia spectrum disorders (2022)
- Application of positron emission tomography in psychiatry-methodological developments and future directions (2022)
- Subcortical volumes across the lifespan (2022)
- No evidence for transmission of psychosis, bipolar or depressive disorder via hematopoietic stem cell transplantation (2022)
- Cortical thickness across the lifespan (2022)
- Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia. (2022)
- A meta-analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA Consortium (2022)
- Facial affect recognition in first-episode psychosis is impaired but not associated with psychotic symptoms. (2022)
- Exhaustion disorder (2022)
- Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia. (2022)
- Thalamic dopamine D2-receptor availability in schizophrenia (2022)
- Identification of cerebrospinal fluid and serum metabolomic biomarkers in first episode psychosis patients (2022)
- Plasma bilirubin levels are reduced in first-episode psychosis patients and associates to working memory and duration of untreated psychosis. (2021)
- Effects of acute glial cell activation on memory performance - Implications for treatment of cognitive symptoms in neurological and psychiatric disorders. (2021)
- Low convergent validity of [11C]raclopride binding in extrastriatal brain regions (2021)
- Nondisplaceable Binding Is a Potential Confounding Factor in 11C-PBR28 Translocator Protein PET Studies. (2021)
- No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis (2021)
- Meta-analysis of the Glial Marker TSPO in Psychosis Revisited (2021)
- GRK3 deficiency elicits brain immune activation and psychosis (2021)
- Objective and Subjective Sleep in Rheumatoid Arthritis and Severe Seasonal Allergy (2021)
- Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis (2021)
- The genetic architecture of human brainstem structures and their involvement in common brain disorders (2020)
- Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson's disease. (2020)
- Synthesis and Preclinical Evaluation of 6-[18F]Fluorine-α-methyl-l-tryptophan, a Novel PET Tracer for Measuring Tryptophan Uptake (2020)
- Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness (2020)
- Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise (2020)
- Neuroinflammation in psychiatric disorders (2020)
- In response to the letter "[11C]raclopride and extrastriatal binding to D2/3 receptors" (2020)
- Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences. (2020)
- Kinfitr - an open-source tool for reproducible PET modelling (2020)
- Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder (2020)
- CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. (2020)
- Brain glial activation in fibromyalgia (2019)
- Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk (2019)
- PET radioligands for the dopamine D1-receptor (2019)
- Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [11C]PBR28 positron emission tomography (2019)
- Common brain disorders are associated with heritable patterns of apparent aging of the brain (2019)
- Increased peripheral levels of TARC/CCL17 in first episode psychosis patients (2019)
- Meta-analytic studies of the glial cell marker TSPO in psychosis - a question of apples and pears? A commentary on 'Neuroinflammation in schizophrenia (2019)
- Accuracy and reliability of [C-11]PBR28 specific binding estimated without the use of a reference region (2019)
- Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis (2019)
- Reproducible grey matter patterns index a multivariate, global alteration of brain structure in schizophrenia and bipolar disorder (2019)
- D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients (2019)
- Validity and reliability of extrastriatal [C-11]raclopride binding quantification in the living human brain (2019)
- Effects of age, BMI and sex on the glial cell marker TSPO (2019)
- Trait impulsivity is not related to post-commissural putamen volumes (2018)
- Immune sculpting of the psychotic brain? (2018)
- Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients (2018)
- Brain neuroreceptor density and personality traits (2018)
- Serotonin 5-HT1A receptor binding and self-transcendence in healthy control subjects (2018)
- In vivo coupling of tau pathology and cortical thinning in Alzheimer's disease (2018)
- CSF GABA is reduced in first-episode psychosis and associates to symptom severity (2018)
- Increased number of monocytes and plasma levels of MCP-1 and YKL-40 in first-episode psychosis (2018)
- First-episode psychosis patients display increased plasma IL-18 that correlates with cognitive dysfunction (2018)
- Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis (2018)
- Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function (2018)
- Is dopamine D1 receptor availability related to social behavior? (2018)
- [11C]SCH23390 binding to the D-1-dopamine receptor in the human brain (2018)
- Evidence of fatigue, disordered sleep and peripheral inflammation, but not increased brain TSPO expression, in seasonal allergy (2018)
- Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [C-11]PBR28 (2017)
- The Immune Response of the Human Brain to Abdominal Surgery (2017)
- In vivo tau PET imaging in dementia (2017)
- Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration (2017)
- Assessment of simplified ratio-based approaches for quantification of PET [11C] PBR28 data (2017)
- Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex (2017)
- Machine Learning for Large-Scale Quality Control of 3D Shape Models in Neuroimaging (2017)
- Extrastriatal dopamine D2-receptor availability in social anxiety disorder (2017)
- Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain (2016)
- Test-retest reproducibility of [C-11]PBR28 binding to TSPO in healthy control subjects (2016)
- In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects (2016)
- D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants A Randomized Clinical Trial (2015)
- ["Dialogical floor" can become a trap door]. (2015)
- Diurnal and seasonal variation of the brain serotonin system in healthy male subjects (2015)
- [New findings about schizophrenia can provide new diagnostics and treatment]. (2015)
- Assessing brain immune activation in psychiatric disorders (2015)
- Meta-analysis of cognitive performance in drug-naive patients with schizophrenia (2014)
- Dopamine D1 receptor availability is related to social behavior (2014)
- [Greater clarity on scientific competence is needed]. (2013)
- Individual differences in the proneness to have flow experiences are linked to dopamine D2-receptor availability in the dorsal striatum (2013)
- Effects of amphetamine on the human brain opioid system (2013)
- Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder (2012)
- A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel-Based Morphometry (2012)
- Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability (2010)
- PET Studies of D2-Receptor Binding in Striatal and Extrastriatal Brain Regions (2010)
- Thinking Outside a Less Intact Box (2010)
- Dopamine D2 receptor density in the limbic striatum is related to implicit but not explicit movement sequence learning (2010)
- Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning (2009)
- Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum (2008)
- Age-related diurnal effect on D-2 receptor binding (2008)
- [Representatives of the academic psychiatry have a responsibility]. (2008)
- [Coming generation of researchers--a question of fate for psychiatry]. (2007)
- Support for dopaminergic hypoactivity in restless legs syndrome (2006)
- A cross-validation study on the relationship between central D-2 receptor occupancy and serum perphenazine concentration (2004)
- Biological markers for CNS damage in a patient cohort with suspected autoimmune psychiatric disease